Linked Life Data

15956649

Source:http://linkedlifedata.com/resource/pubmed/id/15956649

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-6-15
pubmed:abstractText
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/AKT1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine, http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase, http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Phosphoric Monoester Hydrolases, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins, http://linkedlifedata.com/resource/pubmed/chemical/erlotinib, http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1460-2105
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
97
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
880-7
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15956649-Adult, pubmed-meshheading:15956649-Aged, pubmed-meshheading:15956649-Antineoplastic Agents, pubmed-meshheading:15956649-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15956649-Area Under Curve, pubmed-meshheading:15956649-Dacarbazine, pubmed-meshheading:15956649-Drug Administration Schedule, pubmed-meshheading:15956649-Drug Resistance, Neoplasm, pubmed-meshheading:15956649-Female, pubmed-meshheading:15956649-Glioma, pubmed-meshheading:15956649-Humans, pubmed-meshheading:15956649-Immunohistochemistry, pubmed-meshheading:15956649-In Situ Hybridization, Fluorescence, pubmed-meshheading:15956649-Male, pubmed-meshheading:15956649-Middle Aged, pubmed-meshheading:15956649-Mutation, pubmed-meshheading:15956649-PTEN Phosphohydrolase, pubmed-meshheading:15956649-Phosphoric Monoester Hydrolases, pubmed-meshheading:15956649-Phosphorylation, pubmed-meshheading:15956649-Protein-Serine-Threonine Kinases, pubmed-meshheading:15956649-Proto-Oncogene Proteins, pubmed-meshheading:15956649-Proto-Oncogene Proteins c-akt, pubmed-meshheading:15956649-Quinazolines, pubmed-meshheading:15956649-Receptor, Epidermal Growth Factor, pubmed-meshheading:15956649-Supratentorial Neoplasms, pubmed-meshheading:15956649-Tumor Suppressor Proteins
pubmed:year
2005
pubmed:articleTitle
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
pubmed:affiliation
Department of Neurosurgery, Brain Tumor Research Center, University of California-San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143, USA. hkogan@radonc17.ucsf.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase I, Research Support, N.I.H., Extramural